HER2, Fc Fusion, Avi-Tag Recombinant

Only %1 left
Catalog #
102196
As low as $295 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human HER2 (human epidermal growth factor receptor 2), encompassing amino acids 23-652 that correspond to the extracellular portion of the protein. This construct has a human IgG1 Fc domain at the C-terminus, followed by an Avi-Tag™. This protein was affinity purified.

Synonyms
Metastatic lymph node gene 19 protein (MLN 19), Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, Receptor tyrosine-protein kinase erbB-2
Product Info
Storage and Usage
Citations
Species
Human
Construct
HER2 (23-652-Fc(lgG1)-Avi)
Host Species/Expression System
HEK293
Purity

≥90%

Format

Aqueous buffer solution.

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

MW
98 kDa + glycans
Amino Acids
23-652
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank #
NM_004448.4
UniProt #
B2RZG3
Tag(s)
C-terminal Fc-Avi-Tag
Background

HER2 (human epidermal growth factor receptor 2), also known as erbB-2 or CD340, is a tyrosine kinase transmembrane receptor of the EFGR family of proteins. There is no known ligand, but it can form homodimers or heterodimers with other HER proteins. Once active, it activates the MAPK (mitogen-activated protein kinase) and PI3K (phosphatidylinositol-3 kinase) signaling pathways resulting in cell cycle progression and cell proliferation. HER2 over-expression is known to occur in breast, ovarian, stomach, lung adenocarcinoma, aggressive forms of uterine cancer, and gastric cancer. In 1990 the FDA approved the use of the monoclonal antibody trastuzumab in breast and stomach cancer. Other approved strategies to target HER2 include ADCs (antibody-drug conjugate) and margetuximab (anti-HER2 antibody that can induce cytotoxicity). The use of small molecule tyrosine kinase inhibitors, alone or in combinatory therapy, has shown great promise in the treatment of HER2+ breast cancer (BC). However, resistance to treatment, for instance by mutations on HER2 or upregulation of other HER receptors, has been described. Neratinib, a pan-HER2 inhibitor, was approved in 2017 for early-stage BC, as adjuvant anti-HER2 therapy after trastuzumab treatment. However, side effects limit its use. The development of treatments able to target early-stage cancer, with minimal side effects and resistance development, will bring major benefits to HER2+ oncology patients.